Evoke Pharma Investing Activities - Other 2012-2024 | EVOK

Evoke Pharma investing activities - other from 2012 to 2024. Investing activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the investing activities section of the Cash Flows Statement
Evoke Pharma Annual Investing Activities - Other
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.004B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $18.263B 6.36
Dr Reddy's Laboratories (RDY) India $11.391B 16.94
BridgeBio Pharma (BBIO) United States $5.631B 0.00
Aspen Pharmacare (APNHY) South Africa $5.621B 0.00
Bausch Health Cos (BHC) Canada $2.483B 1.89
Amphastar Pharmaceuticals (AMPH) United States $2.126B 12.79
Supernus Pharmaceuticals (SUPN) United States $1.600B 0.00
Taysha Gene Therapies (TSHA) United States $0.578B 0.00
Generation Bio (GBIO) United States $0.244B 0.00
Assembly Biosciences (ASMB) United States $0.080B 0.00
Personalis (PSNL) United States $0.073B 0.00
Acasti Pharma (ACST) Canada $0.025B 0.00
Sol-Gel Technologies (SLGL) Israel $0.021B 0.00
Teligent (TLGT) United States $0.000B 0.00